Risk Factors for Developing Neovascular Glaucoma in Central Retinal Vein Occlusion: Two-Year Real-World Study

被引:0
|
作者
Chou, Yu-Bai [1 ,2 ,3 ]
Chang, Hsin-Ho [2 ]
Chiu, Hsun-, I [2 ]
Chou, Yiing-Jenq [3 ]
Pu, Christy [3 ]
机构
[1] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, 155 Li Nong St,Sec 2, Taipei 112, Taiwan
关键词
Anti-vascular endothelial growth factor; central retinal vein occlusion; neovascular glaucoma; pan-retinal photocoagulation; PANRETINAL PHOTO-COAGULATION; OCULAR NEOVASCULARIZATION;
D O I
10.1080/09286586.2024.2370260
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PurposeTo explore potential risk factors for the development of neovascular glaucoma (NVG) in central retinal vein occlusion (CRVO) over a two-year intensive follow-up period.MethodsThis study reviewed 1545 patients with CRVO between 2005 and 2019 at Taipei Veterans General Hospital. Inclusion was restricted to (1) patients with acute CRVO within 3 months; (2) patients with ocular neovascularization at initial presentation (3) patients had not received any treatment at the time of CRVO; (4) at least bimonthly follow-up schedule over the course of 2 years. The included patients were screened for potential risk factors for developing NVG and assessed with Kaplan-Meier survival analysis and Cox regression model.ResultsAmong the included 123 patients, the cumulative probability of developing NVG was 26.8% (33/123 cases) in overall follow-up period. The mean interval between the onset of CRVO and NVG was 507 days. Neither macular edema nor central macular thickness at baseline was correlated with the development of NVG (p =.104 and .25, respectively). Patients with diabetes mellitus (DM), older age, and poor vision independently played significant risk factors for developing NVG after controlling other covariates. (p =.034, .001, and .013, respectively).ConclusionsPatients presenting with CRVO who have comorbidities such as DM, older age, and worse VA warrant closer attention and intensive follow-up for the development of NVG. Additionally, the statistical analysis indicated that the presence of macular edema, increased central macular thickness, CV events, history of glaucoma, and early PRP within 3 months had no significant impact on the likelihood of developing NVG.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [21] Central retinal vein occlusion and subsequent neovascular glaucoma after adalimumab treatment for psoriasis
    Hsu, C. -K.
    Cheng, C. -Y.
    Hung, J. -H.
    Li, M. L.
    Huang, F. -C.
    Yang, W. -L.
    Lee, J. Y. -Y.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (01) : 72 - 73
  • [22] Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
    Callizo, Josep
    Ziemssen, Focke
    Bertelmann, Thomas
    Feltgen, Nicolas
    Voegeler, Jessica
    Koch, Mirja
    Eter, Nicole
    Liakopoulos, Sandra
    Schmitz-Valckenberg, Steffen
    Spital, Georg
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 2167 - 2179
  • [23] Risk Factors for Central and Branch Retinal Vein Occlusion
    Al-Nawaiseh, Bassam
    Al-Madani, Mousa
    WORLD FAMILY MEDICINE, 2006, 4 (02): : 29 - 32
  • [24] Central retinal vein occlusion and thrombophilia risk factors
    Adamczuk, YP
    Varela, MLI
    Martinuzzo, ME
    Cerrato, GS
    Forastiero, RR
    BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (07) : 623 - 626
  • [25] Two-year outcomes of intravitreal (IVT) ranibizumab for macular oedema secondary to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO)
    Juma, Z.
    Tyagi, P.
    Santiago, C.
    Ionean, A.
    EYE, 2017, 31 : S16 - S16
  • [26] PREVENTING ROLE OF RETINAL PHOTO-COAGULATION IN DEVELOPMENT OF NEOVASCULAR GLAUCOMA FOLLOWING OCCLUSION OF CENTRAL RETINAL VEIN
    RIASKOFF, S
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 1979, 2 (02): : 157 - 157
  • [27] Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study
    Pearce, Ian A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [28] Real-world outcomes of ranibizumab in patients with retinal vein occlusion from the LUMINOUS™ study
    Pearce, Ian
    Parikh, Soumil
    Macfadden, Wayne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [29] Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study
    Lotery, Andrew
    Clemens, Andreas
    Tuli, Raman
    Xu, Xun
    Shimura, Masahiko
    Nardi, Marco
    Ziemssen, Focke
    Dunger-Baldauf, Cornelia
    Tadayoni, Ramin
    EYE, 2022, 36 (08) : 1656 - 1661
  • [30] Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study
    Andrew Lotery
    Andreas Clemens
    Raman Tuli
    Xun Xu
    Masahiko Shimura
    Marco Nardi
    Focke Ziemssen
    Cornelia Dunger-Baldauf
    Ramin Tadayoni
    Eye, 2022, 36 : 1656 - 1661